Format
Sort by
Items per page

Send to

Choose Destination

Best matches for van der Burg SH:

Classification of current anticancer immunotherapies. Galluzzi L et al. Oncotarget. (2014)

Therapeutic cancer vaccines. Melief CJ et al. J Clin Invest. (2015)

High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Linnemann C et al. Nat Med. (2015)

Search results

Items: 1 to 20 of 240

1.

Development of an RNA-based kit for easy generation of TCR-engineered lymphocytes to control T-cell assay performance.

Bidmon N, Kind S, Welters MJP, Joseph-Pietras D, Laske K, Maurer D, Hadrup SR, Schreibelt G, Rae R, Sahin U, Gouttefangeas C, Britten CM, van der Burg SH.

J Immunol Methods. 2018 Apr 20. pii: S0022-1759(18)30025-5. doi: 10.1016/j.jim.2018.04.007. [Epub ahead of print]

PMID:
29684430
2.

Features of Effective T Cell-Inducing Vaccines against Chronic Viral Infections.

Panagioti E, Klenerman P, Lee LN, van der Burg SH, Arens R.

Front Immunol. 2018 Feb 16;9:276. doi: 10.3389/fimmu.2018.00276. eCollection 2018. Review.

3.

T Cells Engaging the Conserved MHC Class Ib Molecule Qa-1b with TAP-Independent Peptides Are Semi-Invariant Lymphocytes.

Doorduijn EM, Sluijter M, Querido BJ, Seidel UJE, Oliveira CC, van der Burg SH, van Hall T.

Front Immunol. 2018 Jan 25;9:60. doi: 10.3389/fimmu.2018.00060. eCollection 2018.

4.

T cells specific for a TAP-independent self-peptide remain naïve in tumor-bearing mice and are fully exploitable for therapy.

Doorduijn EM, Sluijter M, Marijt KA, Querido BJ, van der Burg SH, van Hall T.

Oncoimmunology. 2017 Nov 20;7(3):e1382793. doi: 10.1080/2162402X.2017.1382793. eCollection 2018.

5.

The anti-tumor effect of RANKL inhibition in malignant solid tumors - A systematic review.

de Groot AF, Appelman-Dijkstra NM, van der Burg SH, Kroep JR.

Cancer Treat Rev. 2018 Jan;62:18-28. doi: 10.1016/j.ctrv.2017.10.010. Epub 2017 Nov 2. Review.

6.

Intratumoral HPV16-Specific T Cells Constitute a Type I-Oriented Tumor Microenvironment to Improve Survival in HPV16-Driven Oropharyngeal Cancer.

Welters MJP, Ma W, Santegoets SJAM, Goedemans R, Ehsan I, Jordanova ES, van Ham VJ, van Unen V, Koning F, van Egmond SI, Charoentong P, Trajanoski Z, van der Velden LA, van der Burg SH.

Clin Cancer Res. 2018 Feb 1;24(3):634-647. doi: 10.1158/1078-0432.CCR-17-2140. Epub 2017 Oct 10.

PMID:
29018052
7.

The Potential and Challenges of Exploiting the Vast But Dynamic Neoepitope Landscape for Immunotherapy.

Verdegaal EME, van der Burg SH.

Front Immunol. 2017 Sep 11;8:1113. doi: 10.3389/fimmu.2017.01113. eCollection 2017.

8.

Rationally combining immunotherapies to improve efficacy of immune checkpoint blockade in solid tumors.

Dammeijer F, Lau SP, van Eijck CHJ, van der Burg SH, Aerts JGJV.

Cytokine Growth Factor Rev. 2017 Aug;36:5-15. doi: 10.1016/j.cytogfr.2017.06.011. Epub 2017 Jun 28. Review.

9.

CD4+ T Cell and NK Cell Interplay Key to Regression of MHC Class Ilow Tumors upon TLR7/8 Agonist Therapy.

Doorduijn EM, Sluijter M, Salvatori DC, Silvestri S, Maas S, Arens R, Ossendorp F, van der Burg SH, van Hall T.

Cancer Immunol Res. 2017 Aug;5(8):642-653. doi: 10.1158/2326-6066.CIR-16-0334. Epub 2017 Jun 21.

PMID:
28637878
10.

HPV16 E7 DNA tattooing: safety, immunogenicity, and clinical response in patients with HPV-positive vulvar intraepithelial neoplasia.

Samuels S, Marijne Heeren A, Zijlmans HJMAA, Welters MJP, van den Berg JH, Philips D, Kvistborg P, Ehsan I, Scholl SME, Nuijen B, Schumacher TNM, van Beurden M, Jordanova ES, Haanen JBAG, van der Burg SH, Kenter GG.

Cancer Immunol Immunother. 2017 Sep;66(9):1163-1173. doi: 10.1007/s00262-017-2006-y. Epub 2017 Apr 27.

PMID:
28451790
11.

IDO and galectin-3 hamper the ex vivo generation of clinical grade tumor-specific T cells for adoptive cell therapy in metastatic melanoma.

Melief SM, Visser M, van der Burg SH, Verdegaal EME.

Cancer Immunol Immunother. 2017 Jul;66(7):913-926. doi: 10.1007/s00262-017-1995-x. Epub 2017 Apr 11.

12.

Genetic evolution of uveal melanoma guides the development of an inflammatory microenvironment.

Gezgin G, Dogrusöz M, van Essen TH, Kroes WGM, Luyten GPM, van der Velden PA, Walter V, Verdijk RM, van Hall T, van der Burg SH, Jager MJ.

Cancer Immunol Immunother. 2017 Jul;66(7):903-912. doi: 10.1007/s00262-017-1991-1. Epub 2017 Apr 8.

13.

Impact of (chemo)radiotherapy on immune cell composition and function in cervical cancer patients.

van Meir H, Nout RA, Welters MJ, Loof NM, de Kam ML, van Ham JJ, Samuels S, Kenter GG, Cohen AF, Melief CJ, Burggraaf J, van Poelgeest MI, van der Burg SH.

Oncoimmunology. 2016 Dec 23;6(2):e1267095. doi: 10.1080/2162402X.2016.1267095. eCollection 2017.

14.

The presence of human papillomavirus (HPV) in placenta and/or cord blood might result in Th2 polarization.

Koskimaa HM, Paaso A, Welters MJP, Grénman S, Syrjänen K, van der Burg SH, Syrjänen S.

Eur J Clin Microbiol Infect Dis. 2017 Aug;36(8):1491-1503. doi: 10.1007/s10096-017-2958-z. Epub 2017 Mar 21.

15.

Control of immune escaped human papilloma virus is regained after therapeutic vaccination.

Ma W, Melief CJ, van der Burg SH.

Curr Opin Virol. 2017 Apr;23:16-22. doi: 10.1016/j.coviro.2017.02.005. Epub 2017 Mar 7. Review.

16.

Enforced OX40 Stimulation Empowers Booster Vaccines to Induce Effective CD4+ and CD8+ T Cell Responses against Mouse Cytomegalovirus Infection.

Panagioti E, Boon L, Arens R, van der Burg SH.

Front Immunol. 2017 Feb 20;8:144. doi: 10.3389/fimmu.2017.00144. eCollection 2017.

17.

Standard radiotherapy but not chemotherapy impairs systemic immunity in non-small cell lung cancer.

Talebian Yazdi M, Schinkelshoek MS, Loof NM, Taube C, Hiemstra PS, Welters MJ, van der Burg SH.

Oncoimmunology. 2016 Nov 8;5(12):e1255393. doi: 10.1080/2162402X.2016.1255393. eCollection 2016.

18.

Long-term Survival and Clinical Benefit from Adoptive T-cell Transfer in Stage IV Melanoma Patients Is Determined by a Four-Parameter Tumor Immune Signature.

Melief SM, Visconti VV, Visser M, van Diepen M, Kapiteijn EH, van den Berg JH, Haanen JB, Smit VT, Oosting J, van der Burg SH, Verdegaal EM.

Cancer Immunol Res. 2017 Feb;5(2):170-179. doi: 10.1158/2326-6066.CIR-16-0288. Epub 2017 Jan 10.

19.

Human Papillomavirus Downregulates the Expression of IFITM1 and RIPK3 to Escape from IFNγ- and TNFα-Mediated Antiproliferative Effects and Necroptosis.

Ma W, Tummers B, van Esch EM, Goedemans R, Melief CJ, Meyers C, Boer JM, van der Burg SH.

Front Immunol. 2016 Nov 22;7:496. eCollection 2016.

20.

The importance of correctly timing cancer immunotherapy.

Beyranvand Nejad E, Welters MJ, Arens R, van der Burg SH.

Expert Opin Biol Ther. 2017 Jan;17(1):87-103. Epub 2016 Nov 16. Review.

PMID:
27802061

Supplemental Content

Loading ...
Support Center